Targeting the Prostatic Tumor Microenvironment With PLX3397, a Tumor-Associated Macrophage Inhibitor in Men With Unfavorable Risk Prostate Cancer Undergoing Radiation Therapy and Androgen Deprivation Therapy

Trial Profile

Targeting the Prostatic Tumor Microenvironment With PLX3397, a Tumor-Associated Macrophage Inhibitor in Men With Unfavorable Risk Prostate Cancer Undergoing Radiation Therapy and Androgen Deprivation Therapy

Suspended
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Pexidartinib (Primary) ; Antiandrogens
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Nov 2017 Status changed from recruiting to suspended.
    • 13 Sep 2017 Planned End Date changed from 1 Jun 2017 to 31 dec 2018.
    • 13 Sep 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top